Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (2,501) Arrow Down
Filter Results: (2,501) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (5,444)
    • People  (17)
    • News  (2,078)
    • Research  (2,501)
    • Events  (2)
    • Multimedia  (224)
  • Faculty Publications  (1,873)

Show Results For

  • All HBS Web  (5,444)
    • People  (17)
    • News  (2,078)
    • Research  (2,501)
    • Events  (2)
    • Multimedia  (224)
  • Faculty Publications  (1,873)
← Page 112 of 2,501 Results →
Sort by

Are you looking for?

→Search All HBS Web
  • August 2009 (Revised April 2012)
  • Case

Genzyme's CSR Dilemma: How to Play its HAND

By: Christopher A. Bartlett, Tarun Khanna and Prithwiraj Choudhury
Genzyme, a global biotechnology company, launches a program to develop therapies for neglected diseases (e.g., malaria, TB), giving away the intellectual property. This case focuses on the decision of which diseases, which partnerships, and which markets should... View Details
Keywords: Global Strategy; Health Care and Treatment; Intellectual Property; Corporate Social Responsibility and Impact; Partners and Partnerships; Research and Development; Biotechnology Industry
Citation
Educators
Purchase
Related
Bartlett, Christopher A., Tarun Khanna, and Prithwiraj Choudhury. "Genzyme's CSR Dilemma: How to Play its HAND." Harvard Business School Case 910-407, August 2009. (Revised April 2012.)
  • 28 Jul 2009
  • First Look

First Look: July 28

they cannot spend on marketing the way their competitors do. The case invites students to explore an unusual business model in both concept and execution. Purchase this case: http://cb.hbsp.harvard.edu/cb/product/609106-PDF-ENG Pfizer:... View Details
Keywords: Martha Lagace
  • 19 May 2011
  • Research & Ideas

Empathy: The Brand Equity of Retail

told the story of patient advocate Jackie Gruzenski, who faced an all-too-common experience when her husband was hospitalized for a cerebral bleed in 2009. Gruzenski was only allowed to see her husband during very strict visiting hours for the intensive View Details
Keywords: by Carmen Nobel; Health
  • 02 Apr 2015
  • Research & Ideas

Digital Initiative Summit: The Business of Crowdsourcing

Boston predict which places might be violating public health regulations. And it is working with an education nonprofit in Watertown, Mass., Education Resource Strategies, to study how school districts spend... View Details
Keywords: by Dina Gerdeman
  • 2024
  • Working Paper

Fecal Microbiota Transplants —Too Simple to be Safe? Case Histories of Transformational Advances

By: Amar Bhide and Srikant M. Datar
By 2013, after many decades of very slow development and adoption, Fecal Microbiota Transplantation procedures were attracting widespread attention. This case history chronicles the: 1) pioneering fecal transplants performed in the 20th century; 2) development of the... View Details
Keywords: Health Care and Treatment; Innovation and Invention; Governing Rules, Regulations, and Reforms
Citation
SSRN
Read Now
Related
Bhide, Amar, and Srikant M. Datar. "Fecal Microbiota Transplants —Too Simple to be Safe? Case Histories of Transformational Advances." Harvard Business School Working Paper, No. 21-132, June 2021. (Revised May 2024.)
  • Article

Time-Driven Activity-Based Costing in Emergency Medicine

By: Robert S. Kaplan, Brian J. Yun, Anand M. Prabhakar, Jonathan Warsh, John Brennan, Kyle E. Dempsey and Ali S. Raja
Value in emergency medicine is determined by both patient-important outcomes and the costs associated with achieving them. However, measuring true costs is challenging. Without an understanding of costs, emergency department (ED) leaders will be unable to determine... View Details
Keywords: Time-Driven Activity-Based Costing; Emergency Room; Health Care and Treatment; Value; Cost Management; Activity Based Costing and Management
Citation
Read Now
Related
Kaplan, Robert S., Brian J. Yun, Anand M. Prabhakar, Jonathan Warsh, John Brennan, Kyle E. Dempsey, and Ali S. Raja. "Time-Driven Activity-Based Costing in Emergency Medicine." Annals of Emergency Medicine 67, no. 6 (June 2016): 765–772.
  • August 2017
  • Article

Relationship Between Labor and Delivery Unit Management Practices and Maternal Outcomes

By: Avery C. Plough, Grace Galwin, Zhonghe Li, Stuart R. Lipsitz, Shehnaz Alidina, Natalie J. Henrich, Lisa R. Hirschhorn, William R. Berry, Atul A. Gawande, Doris Peter, Rory McDonald, Donna L. Caldwell, Janet H. Muri, Debra Bingham, Aaron B. Caughey, Eugene R. Declercq and Neel T. Shah
OBJECTIVE: To define, measure, and characterize key competencies of managing labor and delivery units in the United States and assess the associations between unit management and maternal outcomes. METHODS: We developed and administered a management measurement... View Details
Keywords: Health Care and Treatment; Management Practices and Processes; Performance Evaluation; Outcome or Result; United States
Citation
Find at Harvard
Purchase
Related
Plough, Avery C., Grace Galwin, Zhonghe Li, Stuart R. Lipsitz, Shehnaz Alidina, Natalie J. Henrich, Lisa R. Hirschhorn, William R. Berry, Atul A. Gawande, Doris Peter, Rory McDonald, Donna L. Caldwell, Janet H. Muri, Debra Bingham, Aaron B. Caughey, Eugene R. Declercq, and Neel T. Shah. "Relationship Between Labor and Delivery Unit Management Practices and Maternal Outcomes." Obstetrics & Gynecology 130, no. 2 (August 2017): 358–365.
  • 2007
  • Book

Perspectives on Risk and Regulation: The FDA at 100

By: Arthur A. Daemmrich and Joanna Radin
Perspectives on Risk and Regulation: The FDA at 100 brings together the viewpoints of Food and Drug Administration officials and industry leaders on the future of regulating food, drugs, medical devices, and dietary supplements. In a period of rapid scientific... View Details
Keywords: Private Sector; Governing Rules, Regulations, and Reforms; Policy; Health Care and Treatment; Business and Government Relations; Risk and Uncertainty; Cooperation
Citation
Find at Harvard
Read Now
Related
Daemmrich, Arthur A., and Joanna Radin, eds. Perspectives on Risk and Regulation: The FDA at 100. Chemical Heritage Foundation, 2007. (Fulltext.)
  • Summer 2021
  • Article

Predictable Country-level Bias in the Reporting of COVID-19 Deaths

By: Botir Kobilov, Ethan Rouen and George Serafeim
We examine whether a country’s management of the COVID-19 pandemic relate to the downward biasing of the number of reported deaths from COVID-19. Using deviations from historical averages of the total number of monthly deaths within a country, we find that the... View Details
Keywords: COVID-19; Deaths; Reporting; Incentives; Government Policy; Health Pandemics; Health Care and Treatment; Country; Crisis Management; Outcome or Result; Reports; Policy
Citation
Read Now
Related
Kobilov, Botir, Ethan Rouen, and George Serafeim. "Predictable Country-level Bias in the Reporting of COVID-19 Deaths." Journal of Government and Economics 2 (Summer 2021).
  • 05 Jan 2010
  • First Look

First Look: January 5

leading center for diabetes care, clinician training, and research. The incidence of diabetes is rising precipitously worldwide, challenging quality of life with its complications and rapidly accelerating health View Details
Keywords: Martha Lagace
  • August 2008 (Revised May 2009)
  • Background Note

Note on Generic Drugs in the European Union

By: Robert C. Pozen and Elizabeth M. Leonard
Rules governing the introduction of generic drugs in U.S. and EU have some similarities but significant differences because of the Hatch-Waxman Act in the U.S. View Details
Keywords: Governing Rules, Regulations, and Reforms; Government Legislation; Health Care and Treatment; Trademarks; Brands and Branding; Pharmaceutical Industry; European Union; United States
Citation
Find at Harvard
Related
Pozen, Robert C., and Elizabeth M. Leonard. "Note on Generic Drugs in the European Union." Harvard Business School Background Note 309-019, August 2008. (Revised May 2009.)
  • August 2001
  • Case

Scios, Inc.

By: Regina E. Herzlinger
Scios, filled with distinguished scientists and experienced managers, nevertheless fails to clear the FDA Phase III process for an important biotechnology drug. This case asks the students to analyze the social costs and benefits of the regulatory process. View Details
Keywords: Governing Rules, Regulations, and Reforms; Health Care and Treatment; Cost Management; Cost vs Benefits; Social Issues; Pharmaceutical Industry; United States
Citation
Educators
Related
Herzlinger, Regina E. "Scios, Inc." Harvard Business School Case 302-034, August 2001.
  • 09 Oct 2018
  • First Look

New Research and Ideas, October 9, 2018

how should they go to market? Purchase this case:https://hbsp.harvard.edu/product/619014-PDF-ENG Harvard Business School 419-011 Hironobu Tsujiguchi and His Sweet Revolution Hironobu Tsujiguchi, a Japanese chocolatier, had chosen an unusual path to success as a pastry... View Details
Keywords: Dina Gerdeman
  • October 2021 (Revised January 2022)
  • Supplement

Michael Ku and Global Clinical Supply at Pfizer Inc.: Bringing Hope to Patients (C)

By: Linda A. Hill and Emily Tedards
This case is the third installment in a series about the 10-year cultural and digital transformation of Pfizer’s Global Clinical Supply organization. In 2011, Michael Ku became Pfizer’s Vice President of Global Clinical Supply (GCS) after the company had undergone... View Details
Keywords: Clinical Supply Chain; COVID-19; Vaccine; Agile; Innovation and Invention; Change Management; Organizational Culture; Transformation; Leadership; Corporate Strategy; Health Pandemics; Crisis Management; Mission and Purpose; Health Care and Treatment; Supply Chain Management; Digital Transformation
Citation
Purchase
Related
Hill, Linda A., and Emily Tedards. "Michael Ku and Global Clinical Supply at Pfizer Inc.: Bringing Hope to Patients (C)." Harvard Business School Supplement 422-041, October 2021. (Revised January 2022.)
  • 29 Jul 2008
  • First Look

First Look: July 29, 2008

situation facing Gary Gottlieb, president of Brigham and Women's Hospital (BWH), prior to the opening of BWH's integrated cardiovascular center. This case allows students to develop an appreciation of the strategic, financial, organizational, clinical, and physical... View Details
Keywords: Martha Lagace
  • 06 Mar 2012
  • First Look

First Look: March 6

(equipment or software, for example), and using these forms of capital more efficiently. Government spending for many public goods, such as education and infrastructure, contributes directly to one or more of them, whereas View Details
Keywords: Sean Silverthorne
  • 26 Sep 2019
  • Research & Ideas

What Can the World’s Largest Refugee Camp Teach Us About the Meaning of Work?

day.” Testing the unique benefits of work By all accounts, overcrowding, extreme poverty, and the experience of forced displacement inside the camps has taken a profound toll. Doctors Without Borders has provided almost 1.4 million outpatient medical consultations and... View Details
Keywords: by Danielle Kost
  • September 2011
  • Teaching Note

Tengion: Bringing Regenerative Medicine to Life (TN)

By: Elie Ofek and Natalie Kindred
Teaching Note for 510031. View Details
Keywords: Partners and Partnerships; Production; Marketing; Cash; Health Care and Treatment; Medical Specialties; Research and Development; Biotechnology Industry
Citation
Purchase
Related
Ofek, Elie, and Natalie Kindred. "Tengion: Bringing Regenerative Medicine to Life (TN)." Harvard Business School Teaching Note 512-023, September 2011.
  • 15 Dec 2015
  • First Look

December 15, 2015

as opposed to an agency cost. Publisher's link: https://www.hbs.edu/faculty/Pages/item.aspx?num=50200 October 19, 2015 Harvard Business Review Getting Bundled Payments Right in Health Care By: Kaplan, Robert... View Details
Keywords: Carmen Nobel
  • November 2009 (Revised August 2010)
  • Case

NovoCure Ltd.

By: William A. Sahlman and Sarah Flaherty
Venture capitalist William Doyle must raise $35 million for a portfolio company with a promising, novel cancer therapy, just as global capital markets are imploding in the fall of 2008. NovoCure, Ltd., has developed an electrical-field-based therapy, called Tumor... View Details
Keywords: Financial Crisis; Entrepreneurship; Venture Capital; Investment; Health Care and Treatment; Health Testing and Trials; Technological Innovation; Financial Services Industry
Citation
Educators
Purchase
Related
Sahlman, William A., and Sarah Flaherty. "NovoCure Ltd." Harvard Business School Case 810-045, November 2009. (Revised August 2010.)
  • ←
  • 112
  • 113
  • …
  • 125
  • 126
  • →

Are you looking for?

→Search All HBS Web
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College.